Corcept Therapeutics ((CORT)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Corcept Therapeutics is currently recruiting for a Phase 1 clinical study titled ‘Evaluation of Miricorilant on Liver Fat in Patients With MASLD.’ The study aims to assess the effect of Miricorilant on hepatic lipids in patients with presumed Metabolic Dysfunction-Associated Steatohepatitis (MASH). This research is significant as it targets a prevalent liver condition with limited treatment options.
The intervention being tested is Miricorilant, an experimental drug administered orally at a dose of 100 mg daily for four weeks. The purpose of this treatment is to reduce liver fat in affected patients.
The study follows an interventional design with a single-group model and no masking, focusing on treatment as its primary purpose. This straightforward approach allows for direct observation of Miricorilant’s effects.
Key dates for this study include its start date on April 21, 2025, and the last update on August 11, 2025. These dates are crucial for tracking the study’s progress and ensuring timely updates for stakeholders.
From a market perspective, positive outcomes from this study could enhance Corcept Therapeutics’ stock performance by demonstrating the potential of Miricorilant in addressing liver conditions. This could also influence investor sentiment positively, especially in comparison to competitors lacking similar advancements.
The study is ongoing, and further details are available on the ClinicalTrials portal.